Similar articles

• [Pharmacotherapy in the treatment of obesity].

  Hamann A. Hamann A. MMW Fortschr Med. 2006 Mar 2;148(9):36-8. doi: 10.1007/BF03364581. MMW Fortschr Med. 2006. PMID: 16566392 Review. German.
• What is the long-term efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity in primary care?

  Leiser JP, Gunning K. Leiser JP, et al. J Fam Pract. 2000 Jun;49(6):572-3. J Fam Pract. 2000. PMID: 10923560 No abstract available.
• [New drugs for the treatment of obesity].

  Mustajoki P. Mustajoki P. Duodecim. 1999;115(20):2191, 2193-4. Duodecim. 1999. PMID: 11973921 Finnish. No abstract available.
• [Weight reduction. Antiobesity drug treatment in type-2 diabetics].

  Verspohl EJ. Verspohl EJ. Pharm Unserer Zeit. 2002;31(3):300-7. doi: 10.1002/1615-1003(200205)31:3<300::AID-PAUZ300>3.0.CO;2-C. Pharm Unserer Zeit. 2002. PMID: 12071127 Review. German. No abstract available.
• [Pharmacotherapy of obesity].

  Svendsen OL. Svendsen OL. Ugeskr Laeger. 2004 Oct 18;166(43):3814-7. Ugeskr Laeger. 2004. PMID: 15544112 Danish. No abstract available.